Two Early Studies Evaluating Potential First-in-Class CELMoD ™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
Phase 1b DLBCL-001 study reinforces promising activity and combinability of golcadomide with R-CHOP in patients with previously untreated aggressive B-cell lymphoma
Phase 1/2 CC-99282-NHL-001 study demonstrate s activity and combinability with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 11, 2023 Category: Pharmaceuticals Source Type: clinical trials
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors
Naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 11, 2023 Category: Pharmaceuticals Source Type: clinical trials
Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials
Data collectively highlight revumenib ' s combination potential with current standard of care agents and support advancement into pivotal combination trials in the frontline setting
100% CRc observed in BEAT AML trial exploring revumenib in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 11, 2023 Category: Pharmaceuticals Source Type: clinical trials
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR)
Results from a Phase 1 expansion cohort showed a 48% ORR and 30% CR in patients who had... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 10, 2023 Category: Pharmaceuticals Source Type: clinical trials
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
Updated results presented at ASH demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration of response and 24-month median duration of CR
Oral presentation showcased overall maintenance of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 10, 2023 Category: Pharmaceuticals Source Type: clinical trials
New Hybrid Treatment Forces Cancer Cells to Starve
NEW YORK, Dec. 9, 2023. The combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows.
The work addressed multiple myeloma, a cancer that forms in blood cells that normally fight... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 10, 2023 Category: Pharmaceuticals Source Type: clinical trials
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
Marstacimab reduced annualized bleeding rate by 35% and 92% compared to routine prophylaxis and on-demand treatment in patients with hemophilia A and B without inhibitors, respectively
Consistent reduction in bleeding rates observed after an... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 9, 2023 Category: Pharmaceuticals Source Type: clinical trials
Genentech ’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone
The inavolisib combination has the potential to address resistance to treatment and poor... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 8, 2023 Category: Pharmaceuticals Source Type: clinical trials
Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
RAHWAY, N.J.--(BUSINESS WIRE) December 7, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced full results from the non-registrational Phase 2 KeyVibe-002 trial evaluating vibostolimab/pembrolizumab, an... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 7, 2023 Category: Pharmaceuticals Source Type: clinical trials
NIH Clinical Trial of Tuberculous Meningitis Drug Regimen Begins
December 7, 2023 -- A trial of a new drug regimen to treat tuberculous meningitis (TBM) has started enrolling adults and adolescents in several countries where tuberculosis (TB) is prevalent. The Improved Management with Antimicrobial Agents... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 7, 2023 Category: Pharmaceuticals Source Type: clinical trials
Vesper Bio doses first volunteer in Phase I study of first-in-class oral treatment for Frontotemporal Dementia
COPENHAGEN, Denmark, Dec. 7, 2023. Vesper Bio ApS ( " Vesper " or " the Company " ), a clinical stage biotech and world leader in sortilin receptor biology, today announces that the first volunteer has been dosed with its lead compound VES001, a patient... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 7, 2023 Category: Pharmaceuticals Source Type: clinical trials
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
71% objective response rate, with 46% achieving a complete response or better after 11 months of median follow-up
Data to be submitted to regulatory authorities, with Biologics License Application on track to be submitted to the FDA this... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 7, 2023 Category: Pharmaceuticals Source Type: clinical trials
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
SAN JOSE, Calif., Dec. 6, 20203. Anixa Biosciences ( " Anixa " or the " Company " ), a biotechnology company focused on the treatment and prevention of cancer, today announced new and updated positive results from the Phase 1 clinical trial of its... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 7, 2023 Category: Pharmaceuticals Source Type: clinical trials
Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors
WALTHAM, Mass., Dec. 5, 2023. Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced it recently dosed its first patient in a Phase 1/1b study of the Company ' s proprietary IL-2... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 6, 2023 Category: Pharmaceuticals Source Type: clinical trials
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody
Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed partial responses
Data support continued evaluation of casdozokitug in combination with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 6, 2023 Category: Pharmaceuticals Source Type: clinical trials
